GlassScriptPhysician profile
Corey J Sievers
NPI 1922217835
$6,321.09
in general payments reported to CMS, 2019-2025
23 companies · $1,149 in 2025
The $1,149 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,264 · 2020: $65.96 · 2021: $24.77 · 2022: $245 · 2023: $110 · 2024: $463 · 2025: $1,149.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,652 · Education: $69.92.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,651.51 |
| Education | $69.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $3,907.48 | 2019 | |
| Abbvie INC. | $1,149.12 | 2019-2025 | Rinvoq |
| Takeda Pharmaceuticals U.S.A., INC. | $245.85 | 2019-2025 | Entyvio |
| Janssen Biotech, INC. | $179.16 | 2019-2025 | Tremfya |
| Pfizer INC. | $172.22 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $119.08 | 2019-2025 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $70.88 | 2019-2023 | Ocaliva |
| Ipsen Biopharmaceuticals, INC | $57.52 | 2024-2025 | Iqirvo |
| Phathom Pharmaceuticals, INC. | $52.80 | 2024-2025 | Voquezna |
| Evoke Pharma, INC. | $43.77 | 2024-2025 | |
| Vivus LLC | $42.86 | 2019 | |
| Ardelyx, INC. | $39.18 | 2024-2025 | Ibsrela |
| Qol Medical, LLC | $38.41 | 2019-2025 | Sucraid |
| Ironwood Pharmaceuticals, INC | $29.54 | 2019-2022 | |
| Concordia Pharmaceuticals INC. | $27.05 | 2019 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $25.93 | 2024 | |
| Ferring Pharmaceuticals INC. | $23.63 | 2024 | Rebyota |
| Olympus America INC. | $21.73 | 2023 | Endoclot Phs |
| Regeneron Healthcare Solutions, INC. | $20.03 | 2024 | Dupixent |
| Redhill Biopharma INC. | $16.27 | 2020 | |
| Aimmune Therapeutics, INC. | $13.93 | 2025 | Zenpep |
| Braintree Laboratories, INC. | $13.59 | 2021 | |
| Portola Pharmaceuticals, LLC | $11.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Corey Sievers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.